TB and MDR-TB: What is new in 2012?

Marina Tadolini, Rosella Centis, Lia D'Ambrosio, Giovanni Battista Migliori

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In 2007, the 125th anniversary of the discovery of Mycobacterium tuberculosis by Robert Koch followed a particularly significant year in the history of tuberculosis (TB) as, in the same year, the World Health Organization and other international organisations published a series of pillar documents and guidelines that set the pathway to improve the control of TB at the global level. Among these, we can mention the Stop TB Strategy, the guidelines on drug-resistant TB management, the Global Plan to Stop TB 2006-2015 and the International Standard of TB Care. Despite the positive results obtained with the implementation of the new recommendations, some crucial gaps remained urgent, such as the need for innovative diagnostic tools for the prompt diagnosis of TB, the rapid identification of drug-resistant strains and the development of new drugs to combat the increasing number of drug-resistant forms of TB. This year, 130 years after Robert Koch's discovery, we can recognise that some of these requests have been met. This article will describe the progresses made in different fields including: laboratory diagnosis and the experience with Xpert1 MTB/RIF assay; multi/extensively drug resistant-TB management and development of new promising drugs; implementation of TB/HIV collaborative activities.

Original languageEnglish
Pages (from-to)101-111
Number of pages11
JournalBreathe
Volume9
Issue number2
DOIs
Publication statusPublished - 2012

Fingerprint

Multidrug-Resistant Tuberculosis
Tuberculosis
Extensively Drug-Resistant Tuberculosis
Pharmaceutical Preparations
Guidelines
Clinical Laboratory Techniques
Anniversaries and Special Events
Standard of Care
Mycobacterium tuberculosis
History
HIV
Organizations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

TB and MDR-TB : What is new in 2012? / Tadolini, Marina; Centis, Rosella; D'Ambrosio, Lia; Migliori, Giovanni Battista.

In: Breathe, Vol. 9, No. 2, 2012, p. 101-111.

Research output: Contribution to journalArticle

Tadolini, Marina ; Centis, Rosella ; D'Ambrosio, Lia ; Migliori, Giovanni Battista. / TB and MDR-TB : What is new in 2012?. In: Breathe. 2012 ; Vol. 9, No. 2. pp. 101-111.
@article{a3482be49f9247edba96faa4a2ee622f,
title = "TB and MDR-TB: What is new in 2012?",
abstract = "In 2007, the 125th anniversary of the discovery of Mycobacterium tuberculosis by Robert Koch followed a particularly significant year in the history of tuberculosis (TB) as, in the same year, the World Health Organization and other international organisations published a series of pillar documents and guidelines that set the pathway to improve the control of TB at the global level. Among these, we can mention the Stop TB Strategy, the guidelines on drug-resistant TB management, the Global Plan to Stop TB 2006-2015 and the International Standard of TB Care. Despite the positive results obtained with the implementation of the new recommendations, some crucial gaps remained urgent, such as the need for innovative diagnostic tools for the prompt diagnosis of TB, the rapid identification of drug-resistant strains and the development of new drugs to combat the increasing number of drug-resistant forms of TB. This year, 130 years after Robert Koch's discovery, we can recognise that some of these requests have been met. This article will describe the progresses made in different fields including: laboratory diagnosis and the experience with Xpert1 MTB/RIF assay; multi/extensively drug resistant-TB management and development of new promising drugs; implementation of TB/HIV collaborative activities.",
author = "Marina Tadolini and Rosella Centis and Lia D'Ambrosio and Migliori, {Giovanni Battista}",
year = "2012",
doi = "10.1183/20734735.025312",
language = "English",
volume = "9",
pages = "101--111",
journal = "Breathe",
issn = "1810-6838",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - TB and MDR-TB

T2 - What is new in 2012?

AU - Tadolini, Marina

AU - Centis, Rosella

AU - D'Ambrosio, Lia

AU - Migliori, Giovanni Battista

PY - 2012

Y1 - 2012

N2 - In 2007, the 125th anniversary of the discovery of Mycobacterium tuberculosis by Robert Koch followed a particularly significant year in the history of tuberculosis (TB) as, in the same year, the World Health Organization and other international organisations published a series of pillar documents and guidelines that set the pathway to improve the control of TB at the global level. Among these, we can mention the Stop TB Strategy, the guidelines on drug-resistant TB management, the Global Plan to Stop TB 2006-2015 and the International Standard of TB Care. Despite the positive results obtained with the implementation of the new recommendations, some crucial gaps remained urgent, such as the need for innovative diagnostic tools for the prompt diagnosis of TB, the rapid identification of drug-resistant strains and the development of new drugs to combat the increasing number of drug-resistant forms of TB. This year, 130 years after Robert Koch's discovery, we can recognise that some of these requests have been met. This article will describe the progresses made in different fields including: laboratory diagnosis and the experience with Xpert1 MTB/RIF assay; multi/extensively drug resistant-TB management and development of new promising drugs; implementation of TB/HIV collaborative activities.

AB - In 2007, the 125th anniversary of the discovery of Mycobacterium tuberculosis by Robert Koch followed a particularly significant year in the history of tuberculosis (TB) as, in the same year, the World Health Organization and other international organisations published a series of pillar documents and guidelines that set the pathway to improve the control of TB at the global level. Among these, we can mention the Stop TB Strategy, the guidelines on drug-resistant TB management, the Global Plan to Stop TB 2006-2015 and the International Standard of TB Care. Despite the positive results obtained with the implementation of the new recommendations, some crucial gaps remained urgent, such as the need for innovative diagnostic tools for the prompt diagnosis of TB, the rapid identification of drug-resistant strains and the development of new drugs to combat the increasing number of drug-resistant forms of TB. This year, 130 years after Robert Koch's discovery, we can recognise that some of these requests have been met. This article will describe the progresses made in different fields including: laboratory diagnosis and the experience with Xpert1 MTB/RIF assay; multi/extensively drug resistant-TB management and development of new promising drugs; implementation of TB/HIV collaborative activities.

UR - http://www.scopus.com/inward/record.url?scp=84870758147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870758147&partnerID=8YFLogxK

U2 - 10.1183/20734735.025312

DO - 10.1183/20734735.025312

M3 - Article

AN - SCOPUS:84870758147

VL - 9

SP - 101

EP - 111

JO - Breathe

JF - Breathe

SN - 1810-6838

IS - 2

ER -